INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46h ago
HOUSE PTR6h ago
SEC 13F6h ago
ROBINHOOD CHAIN6h ago
HOUSE PTR/PurchaseVerified data

Gilbert Ray Cisneros, Jr. bought SUPN

Self · Indivior Pharmaceuticals, Inc. · Supernus Pharmaceuticals, Inc. - Common Stock

Side
BUY
Value range
$1,001 – $15K
Shares
Not disclosed
Price
—
Executed
Mar 3, 2026
Disclosed
Apr 7, 2026
Disclosure timeline35 days from execution to publication · legal deadline 45 days
Mar 3 executedApr 7, 2026 disclosed

SUPN · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
28/ 100 · ROUTINE
Methodology →
  • Transaction type+14 / 20

    Purchase

  • Relative size+2 / 25

    Disclosed range starting at $1K

  • Filing timing+4 / 15

    Disclosed 35 days after execution (STOCK Act deadline: 45)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SUPN

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    36
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Open-market purchase
    		BUY$54K
    1,500 sh
    		Aug 27, 2026Aug 27, 2026
    traded Aug 27, 2026
    		+0dSEC FORM 4

    Evidence

    20
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$707K
    18.6K sh
    		Jun 11, 2026Jun 12, 2026
    traded Jun 11, 2026
    		+1dSEC FORM 4

    Evidence

    23
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.36M
    36.0K sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    17
    RB
    Ryan BarbaraDirector
    INDVIndivior Pharmaceuticals, Inc.
    Grant or award
    		A—
    6,518 sh
    		May 13, 2026May 14, 2026
    traded May 13, 2026
    		+1dSEC FORM 4

    Evidence

    17
    HK
    Humphreys KeithDirector
    INDVIndivior Pharmaceuticals, Inc.
    Grant or award
    		A—
    6,518 sh
    		May 13, 2026May 14, 2026
    traded May 13, 2026
    		+1dSEC FORM 4

    Evidence

    12
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$88K
    2,843 sh
    		Mar 14, 2026Mar 17, 2026
    traded Mar 14, 2026
    		+3dSEC FORM 4

    Evidence

    9
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    6,302 sh
    		Mar 14, 2026Mar 17, 2026
    traded Mar 14, 2026
    		+3dSEC FORM 4

    Evidence

    9
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    6,302 sh
    		Mar 14, 2026Mar 17, 2026
    traded Mar 14, 2026
    		+3dSEC FORM 4

    Evidence

    17
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    5,946 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    24.0K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    27
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$265K
    8,283 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    132.6K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    5,946 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    16
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$86K
    2,682 sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    30
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$2.80M
    87.6K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    17
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    86.9K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PR
    Preblick RyanChief Financial Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    113.5K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    101.5K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    26
    HC
    Heidbreder ChristianChief Scientific Officer
    INDVIndivior Pharmaceuticals, Inc.
    Tax withholding
    		F$1.46M
    45.8K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    21
    AD
    Anderson Woodrow DChief Accounting Officer
    INDVIndivior Pharmaceuticals, Inc.
    Option exercise
    		M—
    18.4K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    House Periodic Transaction Report
    Publisher
    Clerk of the U.S. House of Representatives
    Document ID
    20034285

    Timestamps

    Event (reported)
    Mar 3, 2026
    Published
    Apr 7, 2026
    Ingested by INSIDER
    Nov 5, 06:47 UTC
    Last re-read
    Nov 5, 06:47 UTC

    Extracted facts

    Filer
    Gilbert Ray Cisneros, Jr.
    Role
    Self
    Transaction
    PurchaseAs filed: “P”
    Asset
    Supernus Pharmaceuticals, Inc. - Common Stock
    Ticker
    SUPN
    Reported value
    $1,001 – $15KAs filed: “$1,001 - $15,000”
    Execution date (reported)
    Mar 3, 2026
    Notification date (reported)
    Apr 6, 2026
    Days from execution to publication
    35

    Calculation

    Midpoint = (low + high) / 2. Used only to rank and sum ranges; the true value can be anywhere in the range.

    • Low: $1,001
    • High: $15,000

    = $8,001

    What this establishes

    Gilbert Ray Cisneros, Jr. reported a purchase of Supernus Pharmaceuticals, Inc. - Common Stock. Members report a value range, not an exact amount, and do not report share counts or prices. Dates are as entered by the filer. A trade report is not evidence of wrongdoing.

    Extraction

    Method
    PDF text extraction
    Confidence
    1.00
    Self
    Gilbert Ray Cisneros, Jr.bioguide:C001123
    Issuer
    Indivior Pharmaceuticals, Inc.cik:0001625297

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.